Targeting Low-voltage Areas with EGM-fractionation to Improve Outcome in Patients with Persistent Atrial Fibrillation

Targeting Low-voltage Areas with EGM-fractionation to Improve Outcome in Patients with Persistent Atrial Fibrillation - SCAR-AF

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

DRKS

Registry ID

DRKS00012430

Enrollment

290

Registered

2017-05-11

Start date

2017-05-22

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I48.1

Interventions

Group 1: Redo-pulmonary vein isolation only Group 2: Redo-pulmonary vein isolation plus substrate-guided ablation approach Group 3: Registry of patients without low-voltage areas

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Patients with symptomatic persistent AF (>7 days and <12 months AF duration) undergoing a redo-ablation procedure (previous procedure(s) had to be PVI only). • Age =18 years

Exclusion criteria

Exclusion criteria: • PVI with additional ablation targets (CFAE, lines other than CTI) during the previous ablation procedure(s) • Paroxysmal AF (including patients that are cardioverted within 7 days after episode onset) • Longstanding persistent AF (>12 months with a continuous episode of AF) • Contra-indication to catheter ablation therapy • LA-diameter >60 mm

Design outcomes

Primary

Measure	Time frame
Occurrence of a documented AF episode > 30 seconds during a follow-up-period of 12 months (without antiarrhythmic drug treatment; recurrences in the blanking period will not be counted as procedural failure) Recurrence testing with 3(-) day holter ecgs after 3, 6 and 12 months. Moreover symptom-triggered-ecgs	—

Secondary

Measure	Time frame
• Occurrence of any atrial arrhythmia (AT, atrial flutter, AF) > 30 seconds during the follow-up period (without antiarrhythmic drug treatment; recurrences in the blanking period will not be counted as procedural failure) Recurrence testing with 3(-) day holter ecgs after 3, 6 and 12 months. Moreover symptom-triggered-ecgs • Procedure time • Incidence of repeat procedures • Procedure-related complications	—

Measure

Time frame

• Occurrence of any atrial arrhythmia (AT, atrial flutter, AF) > 30 seconds during the follow-up period (without antiarrhythmic drug treatment; recurrences in the blanking period will not be counted as procedural failure) Recurrence testing with 3(-) day holter ecgs after 3, 6 and 12 months. Moreover symptom-triggered-ecgs • Procedure time • Incidence of repeat procedures • Procedure-related complications

—

Countries

France, Germany

Contacts

Public ContactChristina Gaus

Universitäts-Herzzentrum Freiburg Bad Krozingen

christina.gaus@universitaets-herzzentrum.de0049-7633-4020

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026